Advertisement

Narrative review of brivaracetam for genetic generalized epilepsies

Published:October 21, 2022DOI:https://doi.org/10.1016/j.seizure.2022.10.009

      Abstract

      Background

      The licensed treatment options for genetic generalized epilepsies are limited although many patients with these conditions require chronic pharmacological management with antiseizure medications and there are no curative surgical treatment options. Brivaracetam is being studied as a new therapeutic option for genetic generalized epilepsies. Method: In order to carry out a narrative review on the efficacy and safety of brivaracetam in genetic generalized epilepsies, a literature research was performed in Pubmed, EMBASE, Cochrane and Clinical Trials.gov databases. Results: Promising results were found with doses ranging from 50 to 200 mg/day in terms of efficacy (with > 50% responder rates between 36 and 84%), tolerability, and short and long-term safety (24–57% drug-associated adverse effects), with most studies reporting adequate retention rates and an absence of serious adverse effects, in monotherapy or as adjuvant therapy, even in refractory epilepsies, special populations and in patients with previous use and/or therapeutic failure with levetiracetam.

      Conclusion

      According to our review, brivaracetam is a valid treatment alternative in patients with genetic generalized epilepsies capable of improving patients’ quality of life by reducing seizure frequency with minimal adverse effects.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Seizure - European Journal of Epilepsy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hirsch E.
        • French J.
        • Scheffer I.
        • Bogacz A.
        • Alsaadi T.
        • Sperling M.
        • et al.
        ILAE definition of the idiopathic generalized epilepsy syndromes: position statement by the ILAE task force on nosology and definitions.
        Epilepsia. 2022; 63 ([Internet]Available from:): 1475-1499https://doi.org/10.1111/epi.17236
        • Strzelczyk A.
        • Kay L.
        • Bauer S.
        • Immisch I.
        • Klein K.M.
        • Knake S.
        • et al.
        Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticus.
        Epilepsia. 2018; 59 ([Internet]Available from:): 1549-1556
        • Stefanatou M.
        • Kapetanou E.V.
        • Kimiskidis V.K.
        • Papaliagkas V.
        • Polychronopoulos P.
        • Markoula S.
        • et al.
        Α multicenter retrospective study evaluating brivaracetam in the treatment of epilepsies in clinical practice.
        Pharmaceuticals. 2021; 14: 1-11
        • Stephen L.J.
        • Brodie MJ.
        Brivaracetam: a novel antiepileptic drug for focal-onset seizures.
        Ther Adv Neurol Disord. 2017; : 1-10https://doi.org/10.1177/1756285617742081
        • Kwan P.
        • Trinka E.
        • Van Paesschen W.
        • Rektor I.
        • Johnson M.E.
        • Lu S.
        Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: Results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial.
        Epilepsia. 2014; 55: 38-46
        • Steinig I.
        • von Podewils F.
        • Möddel G.
        • Bauer S.
        • Klein K.M.
        • Paule E.
        • et al.
        Postmarketing experience with brivaracetam in the treatment of epilepsies: a multicenter cohort study from Germany.
        Epilepsia. 2017; 58: 1208-1216
        • Fonseca E.
        • Guzmán L.
        • Quintana M.
        • Abraira L.
        • Santamarina E.
        • Salas-Puig X.
        • et al.
        Efficacy, retention, and safety of brivaracetam in adult patients with genetic generalized epilepsy.
        Epilepsy Behav. 2020; 102 ([Internet]Available from:)106657https://doi.org/10.1016/j.yebeh.2019.106657
        • Adewusi J.
        • Burness C.
        • Ellawela S.
        • Emsley H.
        • Hughes R.
        • Lawthom C.
        • et al.
        Brivaracetam efficacy and tolerability in clinical practice: a UK-based retrospective multicenter service evaluation.
        Epilepsy Behav. 2020; 106 ([Internet]Available from:)106967https://doi.org/10.1016/j.yebeh.2020.106967
        • Toledo M.
        • Brandt C.
        • Quarato P.P.
        • Schulz A.L.
        • Cleveland J.M.
        • Wagener G.
        • et al.
        Long-term safety, efficacy, and quality of life during adjunctive brivaracetam treatment in patients with uncontrolled epilepsy: an open-label follow-up trial.
        Epilepsy Behav. 2021; 118 ([Internet]Available from:)107897https://doi.org/10.1016/j.yebeh.2021.107897
        • O'Brien T.J.
        • Borghs S.
        • He Q.
        • Schulz A.L.
        • Yates S.
        • Biton V.
        Long-term safety, efficacy, and quality of life outcomes with adjunctive brivaracetam treatment at individualized doses in patients with epilepsy: an up to 11-year, open-label, follow-up trial.
        Epilepsia. 2020; 61: 636-646
        • Meador K.J.
        • Laloyaux C.
        • Elmoufti S.
        • Gasalla T.
        • Fishman J.
        • Martin M.S.
        • et al.
        Time course of drug-related treatment-emergent adverse side effects of brivaracetam.
        Epilepsy Behav. 2020; 111 ([Internet]Available from:)107212https://doi.org/10.1016/j.yebeh.2020.107212
        • Brandt C.
        • Klein P.
        • Badalamenti V.
        • Gasalla T.
        • Whitesides J.
        Safety and tolerability of adjunctive brivaracetam in epilepsy: in-depth pooled analysis.
        Epilepsy Behav. 2020; 103 ([Internet]Available from:)106864https://doi.org/10.1016/j.yebeh.2019.106864
        • Grande-Martín A.
        • Sopelana-Garay D.
        • Pardal-Fernández J.M.
        • Sánchez-Honrubia R.M.
        • Sánchez-Larsen ÁA.
        Exceptional response to brivaracetam in a patient with refractory idiopathic generalized epilepsy and absence seizures.
        Epileptic Disord. 2018; 20: 60-64
        • d'Orsi G.
        • Lalla A.
        • Di Claudio M.T.
        • Valenzano A.
        • Sabetta A.
        • Avolio C.
        Brivaracetam in absence status epilepticus.
        Seizure. 2020; 80 ([Internet].Available from:): 3-4https://doi.org/10.1016/j.seizure.2020.05.015
        • Santamarina E.
        • Parejo Carbonell B.
        • Sala J.
        • Gutiérrez-Viedma Á.
        • Miró J.
        • Asensio M.
        • et al.
        Use of intravenous brivaracetam in status epilepticus: a multicenter registry.
        Epilepsia. 2019; 60: 1593-1601
        • Lafortune J.
        • Deacon C.
        • Clément J.F.
        Brivaracetam: first Canadian experience in an intractable epilepsy population.
        Can J Neurol Sci. 2020; 47: 183-188
        • Stephen L.
        • Brodie M.J.
        Adjunctive brivaracetam – a prospective audit of outcomes from an epilepsy clinic.
        Epilepsy Behav. 2021; 116 (107746): 1-6https://doi.org/10.1016/j.yebeh.2020.107746
        • Verrotti A.
        • Grasso E.A.
        • Cacciatore M.
        • Matricardi S.
        • Striano P.
        Potential role of brivaracetam in pediatric epilepsy.
        Acta Neurol Scand. 2021; 143: 19-26
        • Willems L.M.
        • Bertsche A.
        • Bösebeck F.
        • Hornemann F.
        • Immisch I.
        • Klein K.M.
        • et al.
        Efficacy, retention, and tolerability of brivaracetam in patients with epileptic encephalopathies: a multicenter cohort study from Germany.
        Front Neurol. 2018; 9: 1-8
        • Kälviäinen R.
        • Genton P.
        • Andermann E.
        • Andermann F.
        • Magaudda A.
        • Frucht S.J.
        • et al.
        Brivaracetam in Unverricht-Lundborg disease (EPM1): results from two randomized, double-blind, placebo-controlled studies.
        Epilepsia. 2016; 57: 210-221
        • Ben-Menachem E.
        • Baulac M.
        • Hong S.B.
        • Cleveland J.M.
        • Reichel C.
        • Schulz A.L.
        • et al.
        Safety, tolerability, and efficacy of brivaracetam as adjunctive therapy in patients with focal seizures, generalized onset seizures, or Unverricht–Lundborg disease: an open-label, long-term follow-up trial.
        Epilepsy Res. 2021; 170 ([Internet]Available from:)106526https://doi.org/10.1016/j.eplepsyres.2020.106526
        • Kasteleijn-Nolst Trenité D.G.A.
        • Genton P.
        • Parain D.
        • Masnou P.
        • Steinhoff B.J.
        • Jacobs T.
        • et al.
        Evaluation of brivaracetam, a novel SV2A ligand, in the photosensitivity model.
        Neurology. 2007; 69: 1027-1034
        • Strzelczyk A.
        • Zaveta C.
        • von Podewils F.
        • Möddel G.
        • Langenbruch L.
        • Kovac S.
        • et al.
        Long-term efficacy, tolerability, and retention of brivaracetam in epilepsy treatment: a longitudinal multicenter study with up to 5 years of follow-up.
        Epilepsia. 2021; 62: 2994-3004
        • Zahnert F.
        • Krause K.
        • Immisch I.
        • Habermehl L.
        • Gorny I.
        • Chmielewska I.
        • et al.
        Brivaracetam in the treatment of patients with epilepsy-first clinical experiences.
        Front Neurol. 2018; 9: 3-9
        • Snoeren A.
        • Majoie M.
        • Fasen K.
        • Ijff DM.
        Brivaracetam for the treatment of refractory epilepsy in patients with prior exposure to levetiracetam: a retrospective outcome analysis.
        Seizure. 2022; 96 ([Internet].Available from:): 102-107https://doi.org/10.1016/j.seizure.2022.02.007
        • Hirsch M.
        • Hintz M.
        • Specht A.
        • Schulze-Bonhage A.
        Tolerability, efficacy and retention rate of Brivaracetam in patients previously treated with Levetiracetam: a monocenter retrospective outcome analysis.
        Seizure. 2018; 61 ([Internet]Available from:): 98-103https://doi.org/10.1016/j.seizure.2018.07.017
        • Abraira L.
        • Salas-Puig J.
        • Quintana M.
        • Seijo-Raposo I.M.
        • Santamarina E.
        • Fonseca E.
        • et al.
        Overnight switch from levetiracetam to brivaracetam. Safety and tolerability.
        Epilepsy Behav Rep. 2021; 16 ([Internet]Available from:)100504https://doi.org/10.1016/j.ebr.2021.100504
        • Yates S.L.
        • Fakhoury T.
        • Liang W.
        • Eckhardt K.
        • Borghs S.
        • D'Souza J.
        An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam.
        Epilepsy Behav. 2015; 52: 165-168
        • Foo E.C.
        • Geldard J.
        • Peacey C.
        • Wright E.
        • Eltayeb K.
        • Maguire M.
        Adjunctive brivaracetam in focal and generalized epilepsies: a single-center open-label prospective study in patients with psychiatric comorbidities and intellectual disability.
        Epilepsy Behav. 2019; 99 ([Internet]Available from:)106505https://doi.org/10.1016/j.yebeh.2019.106505
        • Hwang S.T.
        • Stevens S.J.
        • Fu A.X.
        • Proteasa S.V.
        Intractable generalized epilepsy: therapeutic approaches.
        Curr Neurol Neurosci Rep. 2019; 19: 1-10https://doi.org/10.1007/s11910-019-0933-z
        • Stephen L.J.
        • Brodie MJ.
        Pharmacological management of the genetic generalised epilepsies in adolescents and adults.
        CNS Drugs. 2020; 34 ([Internet]Available from:): 147-161
        • Schoemaker R.
        • Wade J.R.
        • Stockis A.
        Brivaracetam population pharmacokinetics in children with epilepsy aged 1 month to 16 years.
        Eur J Clin Pharmacol. 2017; 73: 727-733
        • Liguori C.
        • Manfredi N.
        • Renna R.
        • Izzi F.
        • Pagliuca M.
        • Pagliuca F.
        • et al.
        Comparison of the effectiveness and tolerability of perampanel and brivaracetam: a real-world, observational, retrospective study.
        Epileptic Disord. 2020; 22 (Jun 1): 309-316
        • Matagne A.
        • Margineanu D.G.
        • Kenda B.
        • Michel P.
        • Klitgaard H.
        Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A.
        Br J Pharmacol. 2008; 154: 1662-1671
        • McGuire S.
        • Silva G.
        • Lal D.
        • Khurana D.S.
        • Legido A.
        • Hasbani D.
        • et al.
        Safety and efficacy of brivaracetam in pediatric refractory epilepsy: a single-center clinical experience.
        J Child Neurol. 2020; 35: 102-105
        • Visa-Reñé N.
        • Raspall-Chaure M.
        • Paredes-Carmona F.
        • Coromina J.S.
        • Macaya-Ruiz A.
        Clinical experience with brivaracetam in a series of 46 children.
        Epilepsy Behav. 2020; 107 ([Internet]Available from:)107067https://doi.org/10.1016/j.yebeh.2020.107067
        • Nissenkorn A.
        • Tzadok M.
        • Bar-Yosef O.
        • Ben-Zeev B.
        Treatment with brivaracetam in children – the experience of a pediatric epilepsy center.
        Epilepsy Behav. 2019; 101 ([Internet]Available from:)106541https://doi.org/10.1016/j.yebeh.2019.106541
        • Liu E.
        • Dilley D.
        • McDonough B.
        • Stockis A.
        • Daniels T.
        Safety and tolerability of adjunctive brivaracetam in pediatric patients < 16 years with epilepsy: an open-label trial.
        Pediatr Drugs. 2019; 21 ([Internet]Available from:): 291-301https://doi.org/10.1007/s40272-019-00332-y
        • Paolini S.L.
        • Pilato M.
        • Rajasekaran V.
        • Waters J.F.R.
        • Bagic A.
        • Urban A.
        Outcomes in three cases after brivaracetam treatment during pregnancy.
        Acta Neurol Scand. 2020; 141: 438-441
        • Andres E.
        • Kerling F.
        • Hamer H.
        • Winterholler M.
        Behavioural changes in patients with intellectual disability treated with brivaracetam.
        Acta Neurol Scand. 2018; 138: 195-202
        • Theochari E.
        • Cock H.
        • Lozsadi D.
        • Galtrey C.
        • Arevalo J.
        • Mula M.
        Brivaracetam in adults with drug-resistant epilepsy and psychiatric comorbidities.
        Epilepsy Behav. 2019; 90 ([Internet]Available from:): 129-131https://doi.org/10.1016/j.yebeh.2018.11.032
        • Klein P.
        • Biton V.
        • Dilley D.
        • Barnes M.
        • Schiemann J.
        • Lu S.
        Safety and tolerability of adjunctive brivaracetam as intravenous infusion or bolus in patients with epilepsy.
        Epilepsia. 2016; 57: 1130-1138